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Normal Vascular Function Despite Low Levels of
High-Density Lipoprotein Cholesterol in Carriers of the
Apolipoprotein A-IMilano Mutant
Monica Gomaraschi, PhD; Damiano Baldassarre, PhD; Mauro Amato, PhD; Sonia Eligini, PhD;
Paola Conca, PhD; Cesare R. Sirtori, MD, PhD; Guido Franceschini, PhD; Laura Calabresi, PhD
Background—Carriers of the apolipoprotein A-IMilano (apoA-IM) mutant have very low plasma high-density lipoprotein
cholesterol (HDL-C) levels but do not show any history of premature cardiovascular disease or any evidence of
preclinical vascular disease. HDL is believed to prevent the development of vascular dysfunction, which may well
contribute to HDL-mediated atheroprotection. Whether the low HDL level of apoA-IM carriers is associated with
impaired vascular function is presently unknown.
Methods and Results—The vascular response to reactive hyperemia, assessed by measuring postischemic increase in
forearm arterial compliance, and the plasma concentration of soluble cell adhesion molecules were evaluated in 21 adult
apoA-IM carriers, 21 age- and gender-matched nonaffected relatives (control subjects), and 21 healthy subjects with low
HDL-C (low-HDL subjects). The average plasma HDL-C and apoA-I levels of apoA-IM carriers were remarkably lower
than those of control subjects and significantly lower than those of low-HDL subjects. The postischemic increase in
forearm arterial compliance in the apoA-IM carriers was 2-fold greater than in low-HDL subjects and remarkably similar
to that of control subjects. Plasma soluble cell adhesion molecule levels were similar in apoA-IM carriers and control
subjects but were greater in low-HDL subjects. When incubated with endothelial cells, HDL isolated from apoA-IM
carriers was more effective than HDL from control and low-HDL subjects in stimulating endothelial nitric oxide
synthase expression and activation and in downregulating tumor necrosis factor-–induced expression of vascular cell
adhesion molecule-1.
Conclusions—Despite their very low HDL levels, apoA-IM carriers do not display typical features of impaired vascular
function because of an improved activity of apoA-IM HDL in maintaining endothelial cell homeostasis. (Circulation.
2007;116:2165-2172.)
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The apolipoprotein A-IMilano (apoA-IM) mutation was firstdescribed in 1980 in a family originating from Limone
sul Garda in northern Italy.1 The apoA-IM mutant differs from
wild-type apoA-I by an Arg-to-Cys substitution at position
173 in the primary sequence, which leads to the formation of
disulfide-linked homodimers and heterodimers with apoA-II.2
The apoA-IM carriers are all heterozygotes for the mutation3;
they share a proatherogenic lipid profile, characterized by
very low plasma high-density lipoprotein cholesterol
(HDL-C) levels, normal to somewhat elevated plasma low-
density lipoprotein cholesterol levels, and moderate hypertri-
glyceridemia,4 but they do not show any history of premature
cardiovascular disease3 or any evidence of vascular disease at
a preclinical level.5 This apparent paradox is explained, at
least in part, by an enhanced capacity of serum from apoA-IM
carriers to promote cell cholesterol efflux through the ATP-
binding cassette 1 (ABCA1) transporter.6
Clinical Perspective p 2172
Vascular dysfunction, characterized by an impaired regu-
lation of vascular tone and by a proinflammatory and proad-
hesive state of endothelium, is believed to play a key role in
the development of atherosclerosis.7,8 Impaired vascular re-
sponse has been reported in patients with primary hypoal-
phalipoproteinemia,9–11 and significant inverse correlations
have repeatedly been found between the plasma HDL-C level
and either direct11,12 or indirect13 measures of vascular dys-
function. Even more strikingly, a low plasma HDL-C con-
centration is an independent predictor of impaired peripheral
vasodilation in healthy individuals and in hyperlipidemic,
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diabetic, and coronary patients,14–17 and the elevation of the
plasma HDL concentration in patients with low HDL-C
levels by either drug treatment or infusion of synthetic HDL
leads to a significant improvement of vascular function.10,18
Together, these findings argue for a protective effect of HDL
against the development of vascular dysfunction, which may
well contribute, together with the known HDL function in cell
cholesterol removal and transport, to HDL-mediated preven-
tion of cardiovascular diseases. Whether the low HDL-C
level of apoA-IM carriers is associated with impaired vascular
function is presently unknown. The present study was thus
undertaken to compare vascular function in apoA-IM carriers
and in control subjects with either normal or low HDL-C and
to evaluate the ability of HDL isolated from carriers and
control subjects to maintain endothelial homeostasis in cul-
tured cells.
Methods
Subjects
All apoA-IM carriers living in Limone sul Garda, Italy, who were
between 20 and 70 years of age were invited to be included in a
biochemical and cardiovascular checkup study; of the 25 eligible
subjects, 21 agreed to participate. An equal number of subjects of the
same gender and age were selected among nonaffected relatives
(control subjects) and blood donors with low HDL-C (10th
percentile for age- and gender-matched Italian subjects) attending the
Servizio Immunoematologico Trasfusionale of the Niguarda Hospi-
tal in Milano (low-HDL group).5 All subjects provided informed
consent.
Plasma Lipids and Apolipoproteins
After fasting, blood was collected into tubes containing Na2-EDTA
(final concentration 1 mg/mL); plasma was prepared by low-speed
centrifugation, and aliquots were immediately frozen at 80°C.
Plasma lipid and apolipoprotein levels were measured as described
previously.5
Forearm Arterial Compliance
The forearm arterial compliance (FAC) of the nondominant arm was
measured at rest and during reactive hyperemia by a previously
described plethysmographic method that allowed direct assessment
of the nonlinear FAC–blood pressure curve relative to each single
cardiac cycle.12 Diastolic, systolic, and mean blood pressure were
recorded continuously from the middle finger of the nondominant
arm with a Finapres instrument (Ohmeda, Louisville, Colo). After
baseline measurements were taken (average measurement of 16 to 25
beats obtained in 20 seconds), an ischemic occlusion test was
performed by upper-arm pressure-cuff inflation 30 mm Hg above the
systolic pressure for 3 minutes. After cuff deflation, FAC measure-
ment was performed continuously for an additional 5 minutes. The
area under the FAC–blood pressure curve (FACAUC) was determined
at rest (preischemic FACAUC) and during reactive hyperemia (peak
FACAUC) by calculating the integral between 70 and 130 mm Hg.
Postischemic change in FACAUC was calculated as the difference
between preischemic and peak values and expressed as a percentage
of the preischemic value. A single observer performed all examina-
tions after patients had rested in a supine position for 15 minutes in
a temperature-controlled room. The coefficients of variations for
preischemic and peak FACAUC and postischemic FACAUC change
were 10%.12
Plasma Levels of Soluble Cell Adhesion Molecules
Plasma levels of the soluble forms of vascular cell adhesion
molecule-1 (VCAM-1), intracellular cell adhesion molecule-1
(ICAM-1), and E-selectin were measured by use of commercially
available monoclonal antibody–based ELISA kits (R&D Systems,
Minneapolis, Minn). The assays were performed in duplicate for
each sample. The operator was blinded as to sample classification.
HDL Preparation
HDLs (d1.063 to 1.21 g/mL) were isolated from fasting plasma of
6 apoA-IM carriers (A-IM HDL), 6 control subjects (control HDL),
and 6 low-HDL subjects, all matched for gender and age. Cholesterol
and protein concentrations of HDL preparations were determined by
standard techniques. HDL preparations were dialyzed against steril-
ized saline immediately before use.
Cell Cultures and Treatments
Primary cultures of human umbilical vein endothelial cells
(HUVECs) were purchased from PromoCell (Heidelberg, Germany)
and subcultured for 1 to 3 passages in endothelial growth medium
containing 2% fetal calf serum, endothelial cell growth factor/
heparin (4 L/mL), epidermal growth factor (0.1 ng/mL), and
fibroblast growth factor (1 ng/mL). To investigate the effects of
isolated HDLs on endothelial nitric oxide synthase (eNOS) expres-
sion, cells were incubated overnight with increasing concentrations
(0.57 mmol/L and 1.14 mmol/L cholesterol) of A-IM HDL or control
HDL. To investigate the effects of HDL on eNOS activation by
phosphorylation, cells were harvested after 10 or 20 minutes’
incubation with HDL. To investigate the ability of HDL to down-
regulate cytokine-induced VCAM-1 expression, cells were incubated
overnight with increasing concentrations of A-IM HDL or control
HDL (0.28, 0.57, and 1.14 mmol/L cholesterol), washed with PBS to
remove HDL, and stimulated with tumor necrosis factor- (TNF-;
10 ng/mL) for 4 to 8 hours. At the end of the experiments, cells and
conditioned media were immediately frozen at 20°C.
Western Blotting
Cells were harvested in lysis buffer (20 mmol/L Tris, 4% SDS, 20%
glycerol containing 1 mmol/L EDTA, 1 mmol/L sodium orthovana-
date, 1 mmol/L NaF, 1 g/mL leupeptin, 1 mmol/L benzamidine, 10
g/mL soy trypsin inhibitor, 1 mmol/L PMSF, and 0.5 mmol/L
DTT, pH 6.8). Cell debris was removed by centrifugation (10 000g
for 5 minutes), and protein concentration was determined by the
microbicinchoninic acid assay. Protein (30 g) was separated on
10% SDS-PAGE and then transferred on a nitrocellulose membrane.
After saturation with 5% nonfat dried milk, membranes were
incubated with primary antibodies against total eNOS (BD Bio-
sciences, San Jose, Calif), phosphorylated eNOS (Ser1177, Cell
Signaling Technology, Danvers, Mass), or human VCAM-1 (Exal-
pha Biologicals, Watertown, Mass) and then with horseradish
peroxidase– conjugated secondary antibodies (DakoCytomation,
Glostrup, Denmark). Bands were visualized by enhanced chemilu-
minescence (GE Healthcare Biosciences, Uppsala, Sweden). Mem-
branes were then stripped and reprobed with an antibody against
-actin (Sigma-Aldrich Chemie, Steinheim, Germany). Band densi-
ties were evaluated with a GS-690 Imaging Densitometer and
Multi-Analyst software (Bio-Rad Laboratories, Hercules, Calif).
Reverse-Transcription Polymerase Chain Reaction
Total RNA was extracted from HUVECs with TRIzol reagent
(Invitrogen, Carlsbad, Calif). cDNA was prepared by reverse tran-
scription of 1 g of total RNA with the iScript cDNA synthesis kit
(Bio-Rad) and amplified for 25 cycles with iTaq DNA polymerase
(Bio-Rad) in a MyCycler (Bio-Rad). The following primers were
used: eNOS, sense 5-GACGCTACGAGGAGTGGAAG-3, anti-
sense 5-TAGGCTTTGGGGTTGTCAGG-3; VCAM-1, sense 5-
GAAGATG-GTCGTGATCCTTG-3, antisense 5-ACTTGACTG-
TGATC-GGCTTC-3; and GAPDH, sense 5-CCACCCATGG-
CAAATTCCATGGCA-3, antisense 5-TCTAGACGGCAGGTC-
AGGTCCACC-3. Polymerase chain reaction products were sepa-
rated by electrophoresis on 1% agarose gel, stained with ethidium
bromide, visualized by ultraviolet irradiation, and photographed with
Polaroid film. Band densities were evaluated with a GS-690 imaging
densitometer and Multi-Analyst software (Bio-Rad). VCAM-1 and
eNOS band intensities were normalized by their GADPH values.
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ELISA for VCAM-1
VCAM-1 concentration in conditioned media was evaluated on
MaxiSorp plates (Nunc GmbH & Co, Wiesbaden, Germany) with the
CytoSets matched-antibody-pairs ELISA kit (BioSource Interna-
tional, Camarillo, Calif), according to the manufacturer’s instruc-
tions. The assays were performed in duplicate for each sample. The
operator was blinded as to sample classification.
Statistical Analyses
Results are expressed as meanSEM unless otherwise specified.
Variables with a skewed distribution were log-transformed before
analysis. Differences between groups were evaluated by 1-way
ANOVA. ANCOVA was used to adjust for age, gender, body mass
index, systolic and diastolic blood pressure, smoking habit, total
cholesterol, triglyceride, and apoB differences between groups.
Group differences with P0.05 were considered statistically
significant.
The authors had full access to the data and take full responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
Results
Subjects
Demographic, clinical, and lipid/lipoprotein data of apoA-IM
carriers, healthy low HDL-C subjects (low-HDL), and non-
affected family members (control subjects) are given in
Table 1. The 3 groups were comparable as to gender, age,
body mass index, systolic and diastolic blood pressure, and
percentage of smokers. There were no significant differences
in total and low-density lipoprotein cholesterol or apoB
concentrations among the 3 groups. As expected, apoA-IM
carriers and low-HDL subjects had a significantly lower
average HDL-C level than control subjects; accordingly,
significant reductions were also detected in apoA-I and
apoA-II levels. As previously described,4 the apoA-IM carriers
displayed a moderate hypertriglyceridemia, whereas low-
HDL subjects and control subjects had comparable triglycer-
ide levels.
Forearm Arterial Compliance
Vascular response to reactive hyperemia was assessed in the
3 groups of examined subjects noninvasively by a plethys-
mographic method.12 The marked increase in forearm blood
flow during the early phases of reactive hyperemia is believed
to enhance shear stress, which induces the release of nitric
oxide (NO), with consequent vasodilation19 and increased
arterial compliance.12 Preischemic FAC (FACAUC) was re-
markably similar in the 3 groups of investigated subjects
(Table 2). After cuff deflation, FACAUC increased in all
subjects; however, and as expected given our previous
finding of a direct correlation between plasma HDL-C and
postischemic rise of FACAUC,12 the increase of FACAUC in
low-HDL subjects was half that of control subjects (Table 2).
The postischemic increase of FACAUC in the apoA-IM carriers
was 2-fold greater than in low-HDL subjects and remarkably
similar to that of control subjects (Table 2), which indicates
that despite the severe hypoalphalipoproteinemia, the
apoA-IM carriers displayed a normal vascular response to
reactive hyperemia. When data were adjusted for age, gender,
body mass index, systolic and diastolic blood pressure,
smoking habit, total cholesterol, triglycerides, and apoB, the
apoA-IM carriers still had a higher postischemic increase in
FACAUC than low-HDL subjects.
HDL-Mediated eNOS Expression and Activation
in Cultured Endothelial Cells
Given the central role of NO production via eNOS in
hyperemia-induced vasodilation20 and the proven ability of
isolated HDL to promote eNOS expression and activation in
Table 1. Demographic, Clinical, and Lipid/Lipoprotein Data in ApoA-IM Carriers,
Low-HDL Subjects, and Control Subjects
ApoA-IM Carriers Low-HDL Subjects Control Subjects
n 21 21 21
Male/female 11/10 11/10 11/10
Age, y 42.23.8 43.63.6 40.13.4
BMI, kg/m2 25.10.6 25.60.6 24.10.7
SBP, mm Hg 135.25.3 124.72.5 125.74.3
DBP, mm Hg 84.22.4 77.51.6 79.51.3
Smokers, n 7 6 7
Total cholesterol, mg/dL 189.210.8 191.47.3 202.010.3
LDL cholesterol, mg/dL 131.77.6 133.56.3 127.88.3
HDL-C, mg/dL 19.82.1*† 27.01.4* 49.04.4
Triglycerides, mg/dL 186.023.4* 141.810.7 130.214.1
ApoA-I, mg/dL 78.56.1*† 96.82.9* 131.66.2
ApoA-II, mg/dL 17.31.0*† 26.01.3* 38.71.6
ApoB, mg/dL 103.37.6 96.94.5 86.65.1
ApoA-IM carriers indicates carriers of the apoA-IM mutant; low-HDL, subjects with low HDL-C
selected among blood donors; Controls, non affected relatives from the A-IM kindred3; BMI, body mass
index; SBP, systolic blood pressure; and DBP, diastolic blood pressure.
Data are expressed as meanSEM.
*Significantly different from control subjects.
†Significantly different from low-HDL subjects.
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vitro,18,21 we investigated whether the normal vascular re-
sponse to reactive hyperemia observed in vivo in the apoA-IM
carriers (despite the marked HDL reduction) could be due to
an enhanced capacity of A-IM HDL for eNOS expression/
activation. When added to HUVECs overnight, both A-IM
HDL and control HDL caused a significant increase in eNOS
mRNA and protein abundance, as demonstrated by reverse-
transcription polymerase chain reaction and Western blotting
analysis, but stimulation of eNOS expression was greater
with A-IM HDL than with control HDL (Figure 1). HDL
isolated from low-HDL subjects was as effective as control
HDL in enhancing eNOS protein expression (eNOS/-
actin0.640.03, P0.05 versus A-IM HDL, P0.58 versus
control HDL). The stimulation of eNOS expression by HDL
was dose-dependent (Data Supplement Figure I); at the
highest concentration tested, A-IM HDL, control HDL, and
HDL from low-HDL subjects enhanced eNOS protein by
2.20.2-fold, 1.50.1-fold, and 1.40.1-fold compared with
untreated cells, respectively. When the activities of A-IM
HDL and control HDL were compared in terms of their total
protein (Data Supplement Figure I) or apoA-I (data not
shown) concentrations, A-IM HDL was still superior to
control HDL. In a separate set of experiments, we evaluated
the ability of the various HDL preparations to induce eNOS
activation. HUVECs were incubated with increasing concen-
trations of HDL for 10 and 20 minutes, and eNOS phosphor-
ylation was analyzed by immunoblotting. After 10 minutes of
incubation, both A-IM HDL and control HDL caused a
significant and concentration-dependent elevation of the
phosphorylated/total eNOS ratio (Figure 2); A-IM HDL was
more effective than control HDL, but the difference did not
achieve statistical significance. eNOS activation by HDL
declined at 20 minutes, when again, a nonsignificantly greater
activity of A-IM HDL than control HDL was observed (Figure
2). HDL isolated from low-HDL subjects was as effective as
control HDL in stimulating eNOS activation (at 0.57 mmol/L
cholesterol: phosphorylated/total eNOS0.450.10 at 10
minutes and 0.190.06 at 20 minutes, P0.83 and 0.79
versus control HDL, respectively).
Plasma Concentration of Soluble CAMs
Enhanced endothelial expression of CAMs is a typical feature
of endothelial dysfunction,22 and increased plasma levels of
soluble CAMs have been proposed as an indirect measure of
impaired endothelial function.23 Plasma levels of the soluble
forms of VCAM-1, ICAM-1, and E-selectin in the 3 groups
Table 2. Plethysmographic Data in ApoA-IM Carriers, Low-HDL Subjects, and Control Subjects
ApoA-IM Carriers Low-HDL Subjects Control Subjects
Preischemic FAC(AUC)102 4.9 (3.6–9.2) 6.2 (4.7–8.6) 5.2 (3.9–7.5)
Peak FAC(AUC)102 10.0 (7.1–20.0) 9.8 (8.5–13.7) 11.0 (8.5–15.0)
Postischemic FAC(AUC) increase, % 110.1 (76.2–172.3) 59.1 (46.0–84.1)*† 107.5 (66.9–137.4)
Abbreviations as in Table 1. Results are expressed as median, with interquartile ranges in parentheses. Unit of
FAC(AUC)(mL/100 mL forearm/mm Hg)mm Hg.
*Significantly different from control subjects.
†Significantly different from apoA-IM carriers.
Figure 1. eNOS expression in HDL-
treated HUVECs. A, Reverse-transcription
polymerase chain reaction analysis for
eNOS mRNA levels in untreated cells
(medium) and in cells incubated over-
night with HDL (1.14 mmol/L cholesterol)
isolated from control subjects (control
HDL) or apoA-IM carriers (A-IM HDL).
eNOS mRNA band intensities were nor-
malized by GADPH values. B, Western
blotting analysis of eNOS protein levels
in untreated cells and in cells incubated
overnight with control HDL or A-IM HDL
(1.14 mmol/L cholesterol). eNOS protein
band intensities were normalized by
-actin values. Results are expressed as
meanSEM of 3 separate experiments
with 3 different preparations of control
HDL or A-IM HDL and 2 batches of cells.
*P0.05 vs medium, #P0.05 vs control
HDL.
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of investigated subjects are reported in Table 3. Consistent
with our previous findings in 2 larger cohorts of subjects with
low plasma HDL-C levels,13 the present low-HDL subjects
showed significantly higher plasma levels of soluble
VCAM-1, soluble ICAM-1, and soluble E-selectin than
control subjects (Table 3). By contrast, no significant differ-
ence in plasma soluble CAM levels was found between
apoA-IM carriers and control subjects (Table 3).
HDL-Mediated Inhibition of Endothelial VCAM-1
Expression
HUVECs were preincubated with increasing concentrations
of HDL and stimulated with TNF- before measurement of
VCAM-1 concentration in conditioned media by ELISA.
Cells were washed with PBS before stimulation to remove
HDL and prevent TNF- sequestration.24 A-IM HDL and
control HDL both caused a significant and dose-dependent
inhibition of VCAM-1 release by stimulated cells (Figure 3),
but the inhibition was greater with A-IM HDL. HDL isolated
from low-HDL subjects was as effective as control HDL. At
the highest HDL concentration tested, the VCAM-1 content
in conditioned media was reduced by 80.21.7% with A-IM
HDL, by 50.55.8% with control HDL, and by 52.43.0%
with HDL from low-HDL subjects. When the inhibitory
activities of A-IM HDL and control HDL were compared in
terms of their total protein (Figure 3) or apoA-I (data not
shown) concentrations, A-IM HDL was still superior to
control HDL. The concentration of VCAM-1 in the condi-
tioned media actually reflects cell expression of VCAM-1, as
indicated by Western blotting analysis of cell lysates.
VCAM-1 protein was undetectable in unstimulated cells,
whereas a massive signal was visible after TNF- stimula-
tion; preincubation of cells with either A-IM HDL or control
HDL reduced VCAM-1 protein expression compared with
stimulated cells (Data Supplement Figure II). As previously
shown,25 inhibition of VCAM-1 expression by HDL occurs at
a transcriptional level, as indicated by the HDL-mediated
reduction of VCAM-1 mRNA levels in TNF-–stimulated
cells (Figure 4). A-IM HDL was again more effective than
control HDL in downregulating VCAM-1 mRNA levels
(Figure 4).
Discussion
Historical data on the prevalence of cardiovascular disease in
the A-IM kindred3 and quantitative data on the extent of
preclinical atherosclerosis in apoA-IM carriers5 demonstrate
Figure 2. eNOS activation in HDL-treated HUVECs. Cells were
incubated with control HDL or HDL from apoA-IM carriers (A-IM
HDL) at 0.57 mmol/L (open bars) or 1.14 mmol/L (solid bars)
cholesterol for 10 or 20 minutes. Western blotting analysis for
the phosphorylated and total forms of eNOS was performed,
and the phosphorylated/total eNOS ratios were calculated by
densitometric analysis. Results are expressed as meanSEM of
6 separate experiments with 3 different preparations of control
HDL or A-IM HDL and 2 batches of cells. *P0.05 vs baseline.
Table 3. Plasma Levels of Soluble CAMs in ApoA-IM Carriers,
Low-HDL Subjects, and Control Subjects
ApoA-IM Carriers Low-HDL Subjects Control Subjects
sVCAM-1, ng/mL 550.632.1 656.349.3* 502.625.5
sICAM-1, ng/mL 309.826.9 335.621.5* 267.08.9
sE-selectin, ng/mL 52.34.3 62.94.1* 47.93.0
sVCAM-1 indicates soluble VCAM-1; sICAM-1, soluble ICAM-1; and sE-
selectin, soluble E-selectin. Other abbreviations as in Table 1.
Data are expressed as meanSEM.
*Significantly different from control subjects.
Figure 3. VCAM-1 release in HDL-treated, TNF-–stimulated
HUVECs. Cells were incubated overnight with control HDL () or
HDL from apoA-IM carriers () before stimulation with TNF- for
8 hours. Results are expressed as percentage of VCAM-1 con-
centration in conditioned media of untreated, TNF-–stimulated
HUVECs, meanSEM of 6 separate experiments with 6 different
preparations of control HDL or A-IM HDL, and 2 batches of cells.
*P0.05 vs control HDL.
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that the atherogenic lipid profile and, in particular, the severe
hypoalphalipoproteinemia associated with the apoA-IM muta-
tion do not translate into increased cardiovascular risk. This
apparent paradox has been explained by an enhanced capacity
of A-IM HDL to promote cell cholesterol efflux, the first step
in reverse cholesterol transport.6,26 The present investigation
provides an additional explanation. Direct and indirect mea-
surements of vascular function demonstrate for the first time
that contrary to case subjects with low-HDL who did not have
mutations in candidate genes, and despite the severe hypoal-
phalipoproteinemia, apoA-IM carriers do not have impaired
vascular function. This is likely due to an improved activity
of A-IM HDL to maintain endothelial cell homeostasis, as
indicated by the results of in vitro experiments showing that
HDL isolated from the plasma of apoA-IM carriers is more
efficient than HDL isolated from control plasma in stimulat-
ing eNOS expression and activation and in downregulating
cytokine-induced CAM expression.
Vascular function traditionally has been assessed in hu-
mans by direct measurement of the endothelial cell response
to certain stimuli that trigger the release of NO from the
vascular endothelium to mediate vasorelaxation.27 Reactive
hyperemia is another endothelium-dependent stimulus to
noninvasively evaluate vascular function.20 The remarkable
increase in forearm blood flow during the early phases of
reactive hyperemia enhances shear stress, which in turns
induces NO release to enhance compliance during the mid to
late phase of reactive hyperemia.19 The continuous measure-
ment of FAC change during reactive hyperemia, expressed
here as postischemic FACAUC increase, likely reflects the
individual’s capacity to release NO after a mechanical stim-
ulus.12 An alternative to functional tests in the assessment of
vascular function is the measurement of circulating factors
released by damaged and dysfunctional endothelium.28 Ele-
vated plasma levels of such biomarkers, such as soluble
ICAM-1 and soluble VCAM-1, correlate with impaired
NO-dependent vasodilation,29,30 which substantiates their use
as a clinical tool for the assessment of endothelial dysfunc-
tion.23 A low plasma HDL-C concentration is an independent
predictor of impaired peripheral vasodilation in healthy indi-
viduals and in hyperlipidemic, diabetic, and coronary pa-
tients.14–17 The data provided here for apparently healthy
low-HDL subjects are fully consistent with these previous
findings in showing both a reduced vascular reactivity and an
enhanced plasma concentration of biomarkers of endothelial
dysfunction, which are likely due to a reduced plasma content
of functional HDL. As expected, the average plasma HDL-C
of apoA-IM carriers was remarkably lower than that of control
subjects; it was also significantly lower than that of low-HDL
subjects recruited for the present study. On the basis of the
previously reported direct correlation between plasma
HDL-C and postischemic FACAUC increase,12 it was expected
to be as low as or even lower than that found in low-HDL
subjects. The average postischemic FACAUC increase in the
apoA-IM carriers was instead significantly greater than in
low-HDL subjects and remarkably similar to control subjects.
Similarly, in view of the inverse correlation between plasma
levels of HDL-C and soluble CAMs,13 the apoA-IM carriers
were expected to have plasma soluble CAM concentrations as
high as or even higher than those of low-HDL subjects, but
again, this was not true. Therefore, both direct and indirect
measures unambiguously show that apoA-IM carriers do not
have impaired vascular function, and thus, they behave
differently from other cases with primary hypoalphalipopro-
teinemia, in whom a remarkable vascular dysfunction has
been reported.9,10,13
Considerable effort has been expended to understand the
mechanisms whereby the apoA-IM mutation might be linked
to cardiovascular protection. Previous in vitro experiments
showed an enhanced capacity of A-IM HDL, compared with
HDL isolated from healthy control subjects, to promote cell
cholesterol efflux through both the SR-BI (class B, type 1
scavenger receptor) and ABCA1 pathways.6,26 The present
studies demonstrate that A-IM HDL is also more efficient than
control HDL in enhancing endothelial NO bioavailability and
in downregulating cytokine-induced endothelial CAM ex-
pression. These findings are fully consistent with previous
data showing that treatment of isolated rabbit arteries with
A-IM/phospholipid complexes caused a significant attenuation
of lysophosphatidylcholine-induced impairment of endothe-
lium-dependent vasodilation, whereas complexes made with
wild-type apoA-I, as well as plasma-derived control HDL,
produced a nonsignificant attenuation.31 Together, these ob-
servations indicate that the apoA-IM mutation exerts a gain-
of-function effect against the development of cardiovascular
disease through at least 2 distinct mechanisms: promotion of
Figure 4. VCAM-1 expression in HDL-treated, TNF-–stimulated
HUVECs. Reverse-transcription polymerase chain reaction anal-
ysis for VCAM-1 mRNA levels in untreated, unstimulated cells
(medium), in cells stimulated with TNF- for 4 hours, and in
cells incubated overnight with control HDL or HDL from apoA-IM
carriers (A-IM HDL; 1.14 mmol/L cholesterol) before stimulation
with TNF-. VCAM-1 mRNA band intensities were normalized
by GADPH values. Results are expressed as meanSEM of 6
separate experiments with 6 different preparations of control
HDL or A-IM HDL and 2 batches of cells. *P0.05 vs TNF-.
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cell cholesterol removal from the arterial wall and mainte-
nance of endothelial cell homeostasis. This conclusion is
supported by recent findings in apoA-I/apoE double-
knockout mice, in which the expression of apoA-IM leads to
enhanced macrophage cholesterol efflux and reduced arterial
monocyte infiltration, thus lowering atherosclerosis burden,
compared with mice expressing wild-type apoA-I.32
Low plasma HDL-C concentrations are highly prevalent in
coronary patients, and genetic variation in HDL candidate
genes accounts for a sizable proportion of low HDL-C in the
general population.33 Genetically determined low-HDL
states, however, may be associated with an extremely vari-
able atherosclerosis burden34 and coronary risk.35 Paradig-
matic is the case of molecular defects in the apoA-I gene.
Although complete apoA-I deficiency due to chromosomal
aberration is definitely associated with premature coronary
heart disease,36 even marked reductions of plasma HDL-C
caused by more subtle mutations in the same gene do not
necessarily lead to enhanced coronary risk.34 Carriers of the
apoA-IM mutation, who do not show any structural5 or
functional evidence of vascular disease at the preclinical
level, behave clearly distinctly from carriers of other mis-
sense apoA-I mutations that lead to hypoalphalipoproteine-
mia, such as the apoA-I (L178P) mutation, who instead
present with accelerated carotid arterial wall thickening and
endothelial dysfunction, associated with a severely enhanced
cardiovascular risk.37 This dramatic difference in the clinical
phenotype of carriers of 2 missense mutations in the apoA-I
gene, both of which lead to remarkably similar plasma
HDL-C reductions, illustrates that HDL-C levels per se do not
necessarily reflect the atheroprotective potential of HDL and
highlights the need for novel tools for cardiovascular risk
prediction in individuals with low HDL. Genetic testing
aimed at the identification of the molecular defect that causes
the low-HDL state does not appear to have predictive
properties, except for mutations already known to be associ-
ated with either low or high risk. The assessment of HDL in
terms of function rather than just levels of cholesterol or
apoA-I may provide relevant insight into the atheroprotective
capacity of each individual HDL, but simple, reliable, and
reproducible assays of HDL function are less likely to be
applicable on a large scale or validated against clinical
outcomes. Surrogate markers to assess either atherosclerotic
burden, such as carotid intima-media thickness, or vascular
function, such as those used in the present study, although
influenced by a variety of factors other than HDL, have
already proved to be strong predictors of future cardiovascu-
lar events and appear to be the best tools for the screening of
low-HDL individuals and for prioritizing antiatherogenic
therapies aimed at increasing plasma HDL levels and func-
tion, when these therapies will be made available.
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CLINICAL PERSPECTIVE
Population studies clearly demonstrate that a low plasma high-density lipoprotein cholesterol (HDL-C) concentration is a
strong predictor of future coronary heart disease (CHD). Genetically determined low HDL-C states may, however, be
associated with a widely variable CHD risk. Paradigmatic is the case of molecular defects in the apolipoprotein (apo) A-I
gene. In the present study, we show that carriers of the apoA-IM (Arg173C) mutation, who have very low HDL-C levels,
do not have vascular dysfunction, likely because of an improved activity of their HDL in maintaining endothelial cell
homeostasis. This finding complements previous observations on the lack of preclinical atherosclerosis and premature
CHD in the A-IM kindred. Carriers of other missense apoA-I mutations that lead to low HDL-C, such as the apoA-I (L178P)
mutation, instead present with endothelial dysfunction, accelerated carotid arterial wall thickening, and a severely enhanced
CHD risk. This dramatic difference illustrates that HDL-C levels per se do not necessarily reflect the atheroprotective
potential of HDL and highlights the need for novel tools for CHD risk prediction in individuals with low HDL-C levels.
Genetic testing does not appear to have predictive properties, except for already-known mutations. The assessment of HDL
in terms of function rather than just HDL-C levels may provide relevant insight into the atheroprotective capacity of each
individual HDL, but simple, reliable, and reproducible assays for this purpose are presently unavailable. Surrogate markers
to assess atherosclerotic burden or vascular function appear to be the best tools for screening of low-HDL individuals and
for prioritizing current and future antiatherogenic therapies.
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